Journals Clinical Lymphoma, Myeloma & L...

Clinical Lymphoma, Myeloma & Leukemia
Julie S Braish, Eitan Kugler, Elias Jabbour, Karin Woodman, Farhad Ravandi, Short Nicholas, Nitin Jain, Hagop Kantarjian, Koji Sasaki
BACKGROUND: Nelarabine is a purine analog with demonstrated efficacy in the treatment of T-cell Lymphoblastic Leukemia and Lymphoma (T-ALL/LBL). Despite its efficacy and excellent blood-brain barrier penetration, it has a significant side effect profile which is namely concerning for neurotoxicity. Reported neurotoxicity has varied from mild peripheral neuropathy to debilitating grade 4 neurologic complications including Guillain-Barre like syndrome and myelopathy. PATIENTS AND METHODS: We conducted a single centered, retrospective case series to study patients who developed severe neurotoxicity after receiving nelarabine as part of T-ALL treatment...
June 26, 2024: Clinical Lymphoma, Myeloma & Leukemia
Tanvi H Patel, Frits van Rhee, Samer Al Hadidi
Multiple Myeloma (MM) remains a challenging hematological malignancy despite significant advancements made during the past 2 decades. Outcomes have improved by incorporating immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies into treatment algorithms that include high dose chemotherapy and autologous hematopoietic stem cell transplantation. However, many patients may eventually relapse despite these innovations. Newer therapies targeting B-Cell Maturation Antigen (BCMA) offer promise for patients with relapsed or refractory disease...
June 24, 2024: Clinical Lymphoma, Myeloma & Leukemia
Serena Tharakan, Jonathan Feld, Grace Van Hyfte, John Mascarenhas, Douglas Tremblay
BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a rare and likely underdiagnosed hematologic malignancy. Due to its rarity and nuances in diagnosis, many patients are referred to tertiary referral centers, although many continue to be cared for in the community setting. Given discrepancies in outcomes based on facility type in related myeloid malignancies, we hypothesized that CMML patients treated at academic centers may have improved survival as compared to patients treated at nonacademic centers (NACs)...
June 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
Muhammad Ashar Ali, Wajeeha Aiman, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Nitin Jain, Nicholas J Short, Koji Sasaki
INTRODUCTION: The historical standard of care for Ph+ ALL is chemotherapy plus a tyrosine kinase inhibitor (TKI). Recently chemotherapy-free regimens have shown promising efficacy. We performed a meta-analysis to compare the efficacy of chemotherapy-free regimens for Ph+ ALL. METHODS: We searched PubMed and Embase for chemotherapy-free regimens for Ph+ ALL published between January 2000 and October 2023. Of the 5,348 articles screened, 9 nonrandomized clinical trials enrolling 413 patients were included...
June 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
Patrice Nasnas, Jianhua Ling, Yoheved Gerstein, Sa A Wang, Sanam Loghavi, Danielle Hammond, Guillermo Montalban-Bravo, Jayastu Senapati, Naveen Pemmaraju, Jessie Corredor, Sherry Pierce, Michael Roth, Farhad Ravandi, Branko Cuglievan, Tapan Kadia, Courtney D DiNardo
No abstract text is available yet for this article.
June 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
Wenqiu Wang, Zhihe Liu, Xia Zhao
Castleman disease (CD) is characterized by the proliferation of lymphoid tissue and encompasses a range of disorders that vary in clinical presentation, histopathological features, and therapeutic approaches. This article presents a comprehensive review of the current state of CD research, emphasizing the etiology, pathogenesis, clinical manifestations, diagnostic criteria, treatment options, and prognostic factors. CD is a relatively rare condition infrequently encountered in clinical practice. Certain subtypes of CD progress rapidly and pose a significant threat to patient health...
June 5, 2024: Clinical Lymphoma, Myeloma & Leukemia
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie Gertz, Wilson Gonsalves, Suzanne Hayman, Miriam Hobbs, Yi Lisa Hwa, Taxiarchis Kourelis, Martha Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A Kyle, Vincent Rajkumar, Shaji K Kumar
BACKGROUND: The effect of thrombocytopenia has not been studied in the era of novel treatments in multiple myeloma (MM). OBJECTIVE: To evaluate the clinical characteristics and outcomes in MM patients presenting with thrombocytopenia. MATERIALS: Newly diagnosed MM patients between 2008 and 2018 who received at least 2 novel agents at induction. Thrombocytopenia was defined as a platelet count of less than < 150,000/mm3 . RESULTS: A total of 648 patients were identified...
June 1, 2024: Clinical Lymphoma, Myeloma & Leukemia
Daniil Shmidt, Maksim Mamonkin
Chimeric antigen receptor (CAR T) therapy produced excellent activity in patients with relapsed/refractory B-lineage malignancies. However, extending these therapies to T cell cancers requires overcoming unique challenges. In the recent years, multiple approaches have been developed in preclinical models and some were tested in clinical trials in patients with treatment-refractory T-cell malignanices with promising early results. Here, we review main hurdles impeding the success of CAR T therapy in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), discuss potential solutions, and summarize recent progress in both preclinical and clinical development of CAR T therapy for these diseases...
May 31, 2024: Clinical Lymphoma, Myeloma & Leukemia
Aroog Khaliq, William Wesson, Emerson Logan, Carine Tabak, Muhammad Umair Mushtaq, Tara Lin, Joaquina Baranda, Leyla Shune, Al-Ola Abdallah, Joseph McGuirk, Mehdi Hamadani, Nausheen Ahmed
INTRODUCTION: Existing literature suggests that women are significantly underrepresented in the field of hematology-oncology. Women make up 35.6% of hematologists and data on females as site investigators for pivotal trials and authors in publications of pivotal trials in hematologic malignancies, specifically in the novel niche of Chimeric antigen receptor T cell (CAR-T), is sparse. METHODS: We examined the proportion of women in pivotal trials, screening a total of 2180 studies from PubMed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines...
May 31, 2024: Clinical Lymphoma, Myeloma & Leukemia
Aseel Alsouqi, Jennifer A Woyach
Inhibitors of Bruton's tyrosine kinase (BTK) are among the most widely used therapies for chronic lymphocytic leukemia (CLL) and established a new expectation for efficacy and safety in the treatment of this disease. Currently there are 3 covalent inhibitors of BTK approved for the treatment of CLL: ibrutinib, acalabrutinib, and zanubrutinib. The first-in-class covalent BTK inhibitor is ibrutinib, which as monotherapy has excellent efficacy in the front-line setting with a 7-year progression free survival (PFS) of 59%...
May 31, 2024: Clinical Lymphoma, Myeloma & Leukemia
Kamal Al-Rabi, Mohammad Ma'koseh, Fadwa Al-Qadi, Ali A Hanoon, Waleed Da'na, Abdallah J Asha, Zaid Abdel Rahman, Lina Marie, Omar Shahin, Roa'a Ma'koseh, Akram Al-Ibraheem, Anas Zayed, Abeer Yaseen, Saleh Al-Rabee, Heba Farfoura, Hikmat Abdel-Razeq
BACKGROUND: While Chronic Myeloid Leukemia (CML) is a disease of older adults, there is a growing population of adolescent and young adults (AYAs) with CML. This study evaluated the clinical characteristics and outcomes of CML in AYAs. PATIENTS AND METHODS: Data from medical records of adults with chronic phase CML diagnosed and treated at our center from 2011until 2021were retrospectively analyzed. Age between 18 and 29 years was used to define AYAs. Response to tyrosine kinase inhibitors (TKIs), progression to accelerated phase (AP) or blast crisis (BC), event-free survival (EFS) and overall survival (OS) were compared between AYAs and older adults...
May 25, 2024: Clinical Lymphoma, Myeloma & Leukemia
Heejoo Ko, Seunghoon Han, Sung-Soo Park, Suein Choi, Ja Min Byun, Chang-Ki Min
INTRODUCTION: In light of improved survival rates among multiple myeloma (MM) survivors, we sought to assess their risk of secondary malignancies compared to the general population. MATERIALS AND METHODS: This nationwide population-based case-control cohort study utilized the Korea National Health Insurance Service (KNHIS) database incorporating data from 2009 to 2020. We analyzed a total of 7348 patients diagnosed with MM in the case cohort. We selected a control group of 29,351 individuals from the general population without MM, employing a 1:4 propensity score matching approach...
May 21, 2024: Clinical Lymphoma, Myeloma & Leukemia
Daryl Tan, Jason Yongsheng Chan, Kitsada Wudhikarn, Raymond Siu Ming Wong, Limei Poon, Lalita Norasetthada, Tai-Chung Huang, Eric Tse
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for around 30-60% of all cases. The management of DLBCL in Asia has several unmet needs due to the diversity of the population, the heterogeneity of local clinical guidelines for DLBCL and the wide disparity in resources and healthcare systems across different regions. Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) is widely recognized as the standard first-line treatment for DLBCL; however, alternative regimens are required to improve patient outcomes in challenging subtypes, such as patients with high International Prognostic Index scores, old/frail patients, and patients with double-hit and double-expressor DLBCL or concurrent central nervous system disease...
May 20, 2024: Clinical Lymphoma, Myeloma & Leukemia
Albert Oriol, Roman Hájek, Ivan Spicka, Irwindeep Sandhu, Yael C Cohen, Moshe E Gatt, José Mariz, Michele Cavo, Jesús Berdeja, Kexin Jin, Merav Bar, Prianka Das, Ross La Motte-Mohs, Yu Wang, Deepak Perumal, Luciano J Costa
BACKGROUND: Preclinical studies suggest that combining nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, with pomalidomide/dexamethasone (Pd) with or without elotuzumab, an antisignaling lymphocytic activation molecule F7 monoclonal antibody, may improve multiple myeloma (MM) treatment efficacy. PATIENTS AND METHODS: The phase 3 CheckMate 602 study (NCT02726581) assessed the efficacy and safety of nivolumab plus pomalidomide/dexamethasone (NPd) and NPd plus elotuzumab (NE-Pd)...
May 19, 2024: Clinical Lymphoma, Myeloma & Leukemia
Ajai Chari, Amrita Krishnan, Leo Rasche, Jing Christine Ye, Alfred Garfall, Rakesh Popat, Brea Lipe, Xiang Qin, Michela Campagna, Tara Masterson, Chalmer Tomlinson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, M Damiette Smit, Kathleen Gray, Colleen Kane, Christoph Heuck, Niels W C J van de Donk
BACKGROUND: Talquetamab is a bispecific antibody targeting the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D). In the phase 1/2 MonumenTAL-1 trial (NCT03399799/NCT04634552), overall responses rates were > 71% in patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM). Due to the distribution of the target antigen, a unique pattern of GPRC5D-associated adverse events (AEs) was observed, together with T-cell redirection-associated AEs...
May 15, 2024: Clinical Lymphoma, Myeloma & Leukemia
Rory Bennett, Michael Dickinson
The CD20xCD3 bispecific antibodies (bsAb) are "off-the-shelf" T-cell re-directing therapies that demonstrate remarkable single-agent clinical activity in B-cell lymphomas. Two agents, epcoritamab (epcor) and glofitamab (glofit) have recent global approvals for patients with relapsed/refractory DLBCL (RR DLBCL) following 2 prior treatment lines. Both agents demonstrate activity in patients with prior exposure to chimeric antigen receptor T-cell (CAR-T) treatment. As multiyear follow-up data become available, it is clear that the majority of patients achieving complete remissions do not relapse and that outcomes are similar between epcor and glofit...
May 15, 2024: Clinical Lymphoma, Myeloma & Leukemia
Sanam Loghavi
The 5th edition of the World Health Organization (WHO) classification of Hematolymphoid tumors provides a hierarchically-driven catalog of hematologic neoplasms and introduces a series of changes to the classification of acute myeloid leukemia (AML). Emphasizing molecular genetic findings, it expands the category of "acute myeloid leukemias with defining genetic abnormalities" while retaining the morphologically defined category of AML for cases that do not harbor disease-defining genetic drivers. The updates to the classification of AML provide refined definitions and diagnostic criteria based on clinicopathologic parameters and molecular genetic findings, emphasizing therapeutically and/or prognostically actionable biomarkers...
May 15, 2024: Clinical Lymphoma, Myeloma & Leukemia
Shivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, Amylou Dueck, Douglas Tremblay, John O Mascarenhas, Yelena Ginzburg, Marina Kremyanskaya, Ronald Hoffman
BACKGROUND: Outcomes are dismal for patients with myelofibrosis (MF) who are no longer responsive to JAK2 inhibitors (JAKi) and/or have increasing blast cell numbers. Although prior reports have suggested the benefits of intravenous decitabine (DAC) combined with ruxolitinib for patients with Myeloproliferative Neoplasm (MPN) accelerated/blast phase (AP/BP), decitabine-cedazuridine (DEC-C), an oral fixed-dose combination providing equivalent pharmacokinetic exposure, has not been evaluated in MF...
May 14, 2024: Clinical Lymphoma, Myeloma & Leukemia
Rohtesh S Mehta
The landscape of HLA matching in hematopoietic cell transplantation (HCT) is continuously advancing, introducing more nuanced criteria beyond traditional 10/10 HLA-A, -B, -C, and -DRB1 allele matching. For 10/10 matched donors, prioritizing a donor with a "core" permissive HLA-DPB1 mismatch is recommended over "noncore" permissive mismatches, with nonpermissive mismatches being the least prefered. In the one-antigen mismatched setting (7/8 HLA-matched), HLA-C matching, particularly avoiding high-expression mismatches at residues 116 or 77/80, is preferred over HLA-A or HLA-B mismatches...
May 14, 2024: Clinical Lymphoma, Myeloma & Leukemia
Nilanjan Ghosh, Jeff P Sharman, Meghan Gutierrez, Wasiulla Khan, Zaina P Qureshi, Anat Raz, Vincent Girardi, Gabriel S Krigsfeld, Jacqueline C Barrientos
BACKGROUND: informCLL is the largest US-based prospective, observational registry of patients with chronic lymphocytic leukemia (CLL) initiating FDA-approved treatment in the era of targeted therapy. PATIENTS AND METHODS: Patients were enrolled between October 2015 and June 2019. Data were collected for baseline characteristics, treatment patterns, outcomes, and safety. RESULTS: In total, 1459 eligible patients were enrolled (first line, n = 854; relapsed/refractory, n = 605)...
May 13, 2024: Clinical Lymphoma, Myeloma & Leukemia
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.